Incyte Aktie News

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Announces Change to its Board of Directors.

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #ASH2025--Updated Positive Data at ASH 2025 Reinforce the Potential of Incyte's INCA033989, its First-in-Class mutCALR-Targeted Monoclonal Antibody, in ET.

Incyte Corporation (INCY) Discusses mutCALR Data and Therapeutic Advances in Myeloproliferative Neoplasms at ASH Transcript

The FDA granted Breakthrough Therapy status to Incyte's experimental treatment for a rare blood cancer. Incyte stock is basing near five-year highs.

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #ASH2025--Incyte Announces New Positive Data for INCA033989, its First-In-Class mutCALR-Targeted Monoclonal Antibody, in Patients with MF Presented at ASH 2025.

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #ASH2025--Incyte's First-in-Class mutCALR-Targeted Monoclonal Antibody, INCA033989, Granted Breakthrough Therapy Designation by U.S. FDA.

Incyte Corporation's rapid non-Jakafi portfolio growth and strong operating leverage look decent amid still-cheap valuation, supporting attractive risk-reward over the coming quarters ahead. Q3 revenue beat consensus by 9%, with Jakafi still 58% of sales as rapidly expanding Opzelura, Niktimvo, Monjuvi, and Zynyz materially de-risking concentration on Jakafi. Management guides for flat OpEx and...

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4).